To investigate efficacy of capecitabine combined with oxaliplation and bevacizumab on unresectable metastatic colorectal cancer, and influence on 5-year survival.

A total of 114 patients with unresectable metastatic colorectal cancer in the First People’s Hospital of Zhumadian from June 2008 to June 2014 were selected as the research subjects, and they were divided into study group and control group according to the random number table method, with 57 cases in each group. Control group was treated with capecitabine combined with oxaliplatin, and the study group was treated with bevacizumab based on the treatment of control group. After 3 courses of treatment, the treatment effect was evaluated. The occurrence of serious adverse reactions were compared between the two groups during 3 courses of treatment. The 1-year, 3-year, and 5-year survival rates were compared between the two groups.

During the treatment, 1 case in the study group and 2 cases in control group were out of the group. After 3 courses of treatment, the disease control rate and total remission rate in study group were 91.07%(51/56) and 80.36%(45/56), higher than the 70.91%(39/55) and 61.82%(34/55) in control group (P<0.05). Within 3 courses of treatment, there was no statistically significant difference in the incidence of adverse reaction between the two group (P>0.05). The 1-year survival rate of patients in study group (80.85%, 38/47) was higher than that in control group (61.36%, 27/44),P<0.05; and there was no statistically significant difference in the 1-year and 5-year survival rates between the two groups (P>0.05).

Capecitabine combined with oxaliplatin and bevacizumab for patients with unresectable metastatic colorectal cancer can effectively improve clinical efficacy, ensure drug safety, and prolong survival time.

Colorectal neoplasms; Capecitabine; Oxaliplatin; Bevacizumab; Efficacy; Survival time